No connection

Search Results

Market_movement Score 65 Bullish

Soleno Therapeutics Surges on $2.9 Billion All-Cash Acquisition by Neurocrine Biosciences

Apr 06, 2026 21:40 UTC
SLEO, NUE
Immediate term

Soleno Therapeutics' stock climbed over 32% following Neurocrine Biosciences' $53-per-share buyout offer. The deal, announced April 6, 2026, strengthens Neurocrine's rare-disease portfolio with Soleno's VYKAT XR.

  • Soleno Therapeutics' stock surged 32.31% following a $2.9 billion all-cash buyout by Neurocrine Biosciences.
  • The acquisition includes Soleno's VYKAT XR, the first FDA-approved treatment for hyperphagia in Prader-Willi Syndrome patients.
  • VYKAT XR generated $33 million, $66 million, and $92 million in sales over the last three quarters.
  • Neurocrine holds $2.5 billion in cash and is acquiring a third commercial drug through the deal.
  • The biotech sector saw mixed performance, with the S&P 500 and Nasdaq both rising slightly.
  • Soleno's stock has fallen 96% since its 2014 IPO, making the buyout a major shift for shareholders.

Soleno Therapeutics (SLEO) saw its stock surge 32.31% to $52.26 on Monday, driven by Neurocrine Biosciences' $53-per-share all-cash acquisition offer. The deal, valued at $2.9 billion, has positioned Soleno as a focal point for investors tracking potential regulatory or closing risks. Trading volume spiked to 58 million shares, a 2,148% increase from its three-month average of 2.6 million shares. The acquisition marks a strategic expansion for Neurocrine, which is bolstering its rare-disease portfolio with Soleno's VYKAT XR. The drug, the first and only FDA-approved treatment for hyperphagia in patients with Prader-Willi Syndrome (PWS), was launched in March 2025. It has generated $33 million, $66 million, and $92 million in sales over the last three quarters, respectively. Neurocrine, holding $2.5 billion in cash, is acquiring Soleno to add a third commercial drug to its pipeline. The biotech sector saw mixed performance alongside Soleno's surge. The S&P 500 rose 0.43% to 6,611, while the Nasdaq Composite gained 0.54% to 21,996. Peers like Rezolute and Ligand Pharmaceuticals also saw gains, with Rezolute up 4.49% and Ligand up 1.61%. Deal activity and drug data continue to drive focus within the sector. VYKAT XR's intellectual property is expected to extend through the 2040s, offering long-term potential for Neurocrine. The company is currently trading at 18 times free cash flow, making it a stock to watch as the acquisition progresses. Soleno, which went public in 2014, has seen its stock fall 96% since its IPO, making the buyout a significant development for its shareholders.

Sign up free to read the full analysis

Create a free account to unlock full AI-curated market articles, personalized alerts, and more.

Create Free Account Already have an account? Sign In
Share this article

Stay Ahead of the Markets

Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.

Get Started Free View Plans
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile